NFL BIOSCIENCES: Decision to approve the issuing of its patent in South Korea
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, is announcing that it has received approval from the South Korean intellectual property office for issuing its patent (South Korean application no.10-2018-7032224) for NFL-101, a nicotine-free botanical drug candidate comprising natural proteins extracted from tobacco leaves, focused primarily on smoking cessation. This patent will protect the innovation that NFL-101 is based on through to 2036 in South Korea.
NFL Biosciences has adopted a knowledge management and protection strategy that led it to submit two patent families granting it exclusive rights to its drug candidate NFL-101. This product patent, initially registered and approved in France, concerns an “aqueous extract of tobacco leaves and its use for the treatment of dependence”. The innovation that NFL-101 is based on is therefore protected through to 2036 in France, the United States, China and now South Korea. National registration applications are also in the review phase in the following regions and countries: Japan, Canada, Australia, Brazil, India, Indonesia, Israel, Mexico, Philippines, Eurasia, Saudi Arabia, United Arab Emirates and Nigeria.
South Korea has more than nine million daily smokers1.
“We are continuing to move forward with our patent registration schedule in line with our global strategy. Following China, the securing of this patent in South Korea will further strengthen the protection of the innovation behind NFL-101. We are continuing to build our coverage across Asia, a key region in the fight against smoking and a major market for NFL Biosciences and its drug candidate”, confirms Bruno Lafont, Chief Operating Officer and co-founder of NFL Biosciences.
About NFL Biosciences
NFL Biosciences is a biopharmaceutical company based in the Montpellier area which develops botanical drug candidates for the treatment of addictions. NFL Biosciences’ ambition is to bring new, natural, safer and more effective therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, called NFL-101, is a standardized, nicotine-free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who want to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorders.
The shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at www.nflbiosciences.com
Bruno Lafont – firstname.lastname@example.org – 04 11 93 76 67 Agence Calyptus – email@example.com – 01 53 65 68 68
1 Source: OECD.org (2019)